NRAS and melanoma: To further assess the involvement of the TAK1 signaling pathway in trametinib resistance in NRAS mutant FBXO42 KO melanoma cells, we combined trametinib with takinib, the potent and selective TAK1 inhibitor (Totzke et al., 2017), and tested their inhibition of FBXO42 KO cell growth.